An SMA project report: neural cell-based assays derived from human embryonic stem cells

Area of Science:

• Stem Cell Biology
• Neuroscience
• Genetics

Background:

• Spinal muscular atrophy (SMA) is a severe childhood paralysis cause linked to SMN1 gene defects.
• The SMN2 gene, while similar, cannot fully compensate for SMN1 loss due to splicing issues.
• Human embryonic stem cells (hESCs) show potential for developing novel neurodegenerative disease treatments.

Purpose of the Study:

• To assess the feasibility of creating a SMA cell-based assay using neural cells derived from hESCs.
• To establish a resource for identifying and testing new SMA therapeutics through a collaborative network.

Main Methods:

• Constructed minigene cassettes with reporter genes (luciferase or GFP) to monitor SMN1/SMN2 splicing efficiency.
• Utilized SMN1, SMN2, or CMV promoters to drive reporter gene expression.
• Performed transient transfection of hESC-derived neuroprogenitors in a 96-well format using plasmid DNA or adenoviral vectors.

Main Results:

• Differential reporter gene expression levels were observed, correlating with specific minigene constructs and promoters.
• Luciferase activity was higher with SMN1 splicing minigenes compared to SMN2.
• The CMV promoter yielded higher activity levels than SMN1 and SMN2 promoters.

Conclusions:

• hESC-derived neuroprogenitors represent a viable and promising cell source for developing assays for neurodegenerative disease therapeutics.
• This approach facilitates the screening of potential treatments for SMA and similar conditions.